Design, synthesis, and biological evaluation of novel chrysin derivatives as poly(ADP-ribose) polymerase 1 (PARP1) inhibitors for the treatment of breast cancer

IF 4 2区 医学 Q1 INTEGRATIVE & COMPLEMENTARY MEDICINE
Yao YANG , Jing TONG , Xianshun XIE , Hong CAO , Yong FU , Yong LUO , Shan LIU , Wen CHEN , Ning YANG
{"title":"Design, synthesis, and biological evaluation of novel chrysin derivatives as poly(ADP-ribose) polymerase 1 (PARP1) inhibitors for the treatment of breast cancer","authors":"Yao YANG ,&nbsp;Jing TONG ,&nbsp;Xianshun XIE ,&nbsp;Hong CAO ,&nbsp;Yong FU ,&nbsp;Yong LUO ,&nbsp;Shan LIU ,&nbsp;Wen CHEN ,&nbsp;Ning YANG","doi":"10.1016/S1875-5364(24)60642-4","DOIUrl":null,"url":null,"abstract":"<div><p>In this study, we reported the discovery and structure-activity relationship analysis of chrysin derivatives as a new class of inhibitors targeting poly (ADP-ribose) polymerase 1 (PARP1). Among these derivatives, compound <strong>5d</strong> emerged as the most effective chrysin-based inhibitor of PARP1, with an IC<sub>50</sub> value of 108 nmol·L<sup>−1</sup>. This compound significantly inhibited the proliferation and migration of breast cancer cell lines HCC-1937 and MDA-MB-436 by inducing DNA damage. Furthermore, <strong>5d</strong> induced apoptosis and caused an extended G<sub>1</sub>/S-phase in these cell lines. Molecular docking studies revealed that <strong>5d</strong> possesses a strong binding affinity toward PARP1. <em>In vivo</em>, in a xenograft model, <strong>5d</strong> effectively reduced tumor growth by downregulating PARP1 expression. Overall, compound <strong>5d</strong> shows promise as a potential therapeutic agent for the treatment of BRCA wild-type breast cancer.</p></div>","PeriodicalId":10002,"journal":{"name":"Chinese Journal of Natural Medicines","volume":null,"pages":null},"PeriodicalIF":4.0000,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Chinese Journal of Natural Medicines","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1875536424606424","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"INTEGRATIVE & COMPLEMENTARY MEDICINE","Score":null,"Total":0}
引用次数: 0

Abstract

In this study, we reported the discovery and structure-activity relationship analysis of chrysin derivatives as a new class of inhibitors targeting poly (ADP-ribose) polymerase 1 (PARP1). Among these derivatives, compound 5d emerged as the most effective chrysin-based inhibitor of PARP1, with an IC50 value of 108 nmol·L−1. This compound significantly inhibited the proliferation and migration of breast cancer cell lines HCC-1937 and MDA-MB-436 by inducing DNA damage. Furthermore, 5d induced apoptosis and caused an extended G1/S-phase in these cell lines. Molecular docking studies revealed that 5d possesses a strong binding affinity toward PARP1. In vivo, in a xenograft model, 5d effectively reduced tumor growth by downregulating PARP1 expression. Overall, compound 5d shows promise as a potential therapeutic agent for the treatment of BRCA wild-type breast cancer.

作为聚(ADP-核糖)聚合酶 1 (PARP1) 抑制剂用于治疗乳腺癌的新型蛹素衍生物的设计、合成和生物学评价
在这项研究中,我们发现了一种新的针对聚(ADP-核糖)聚合酶 1(PARP1)的菊脂衍生物,并对其进行了结构-活性关系分析。在这些衍生物中,化合物 5d 是最有效的基于蛹素的 PARP1 抑制剂,其 IC50 值为 108 nmol-L-1。该化合物通过诱导 DNA 损伤,明显抑制了乳腺癌细胞株 HCC-1937 和 MDA-MB-436 的增殖和迁移。此外,5d 还能诱导细胞凋亡,并使这些细胞株的 G1/S 期延长。分子对接研究表明,5d 与 PARP1 有很强的结合亲和力。在体内,在异种移植模型中,5d 通过下调 PARP1 的表达有效地减少了肿瘤的生长。总之,化合物 5d 是一种治疗 BRCA 野生型乳腺癌的潜在药物。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Chinese Journal of Natural Medicines
Chinese Journal of Natural Medicines INTEGRATIVE & COMPLEMENTARY MEDICINE-PHARMACOLOGY & PHARMACY
CiteScore
7.50
自引率
4.30%
发文量
2235
期刊介绍: The Chinese Journal of Natural Medicines (CJNM), founded and sponsored in May 2003 by China Pharmaceutical University and the Chinese Pharmaceutical Association, is devoted to communication among pharmaceutical and medical scientists interested in the advancement of Traditional Chinese Medicines (TCM). CJNM publishes articles relating to a broad spectrum of bioactive natural products, leading compounds and medicines derived from Traditional Chinese Medicines (TCM). Topics covered by the journal are: Resources of Traditional Chinese Medicines; Interaction and complexity of prescription; Natural Products Chemistry (including structure modification, semi-and total synthesis, bio-transformation); Pharmacology of natural products and prescription (including pharmacokinetics and toxicology); Pharmaceutics and Analytical Methods of natural products.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信